OTC:
$LUDG

Invest in a
Stock

– Invest in a company that is dedicated to helping you and your family

– Potentially life-saving technology

– Research has already yielded promising results

– A sound investment for the future

– Get in on the ground floor of a company with massive potential for growth

– Invest in breakthrough healthcare technologies

– Benefit from strong leadership and experienced management

– Grow your portfolio as the company grows and succeeds

Ludwig Announces Engagement of
Marvin S. Hausman MD
as Chief Science Consultant

The potential for growth at Ludwig Enterprises is great because they have hired Dr. Hausman for their scientific advisory board. Dr. Hausman is an experienced Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience. He has held various positions with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx. With this level of experience and expertise, Dr. Hausman will be a valuable asset to Ludwig Enterprises as they continue to develop new and innovative products.

19

July 2022

Ludwig Enterprises has made an excellent decision by hiring Dr. Ambert for their scientific advisory board. With his extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics, Dr. Ambert will be able to help Ludwig Enterprises grow by using these technologies to improve their business processes. He has already shown his ability to make a difference at Nike, Inc., and we have no doubt that he will do the same for Ludwig Enterprises.

His prior employment history includes positions at Intel Corp. and the National Library of Medicine. Dr. Ambert graduated from Oregon Health & Science University with a PhD in Biomedical Informatics.

21

July 2022

Who they are?

Ludwig Enterprises, Inc. has been an innovative technology and health related company. Ludwig is endeavoring to return to and expand healthy living and other health technology products.

Ludwig mRNA Inflammatory index™️

- The Ludwig mRNA Inflammatory index™ can discover hidden gene patterns related to inflammatory causation of specific diseases, establish diagnoses, and show response to treatment.  - The artificial intelligence division with bioinformatics and deep machine learning experts will help the company search, classify, and mine different available biological databases.  - Shares of the company are available for purchase.

Ms. Anne Blackstone named CEO and Sole Director

Anne Blackstone, CRNA, has a strong background in medicine working in many prestigious posts managing healthcare. That led her to managing special projects in health technology which later, introduced her to mRNAforLife where she took over the CEO position with your strong leadership skills and deep knowledge of the importance of the company's products in healthcare.

Dr. Kyle H. Ambert, PhD appointed to LUDWIG’s Scientific Advisory Board

Dr. Ambert is currently Director of Data Science at Nike, Inc., and has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.

AI is the future

The company announced it had established an Artificial Intelligence division to mine biological databases for valuable patient information. Ludwig is utilizing these databases to research and investigate the causes and effects of inflammation within our bodies.

Invest in
One of the Leading Research Firm ​

The Board of Directors believes that returning to our core focus on health technology and healthy living will be in the best interest of Ludwig shareholders. The U.S. healthcare IT market is valued at $96,930.26 Million in 2020, and is projected to reach $344,074.09 Million by 2030, registering a CAGR of 13.4% from 2021 to 2030.

This provides a strong foundation for Ludwig’s future growth and profitability. Additionally, Ludwig has a strong track record of innovation and success in the healthcare technology market, which we believe will give us a competitive edge in this growing sector. For these reasons, the Board of Directors believes that Ludwig is a good investment for shareholders.

Before patents and major announcements affect the stock.

It is wise to buy a stock at its lowest.*

Get in on the ground floor of a quickly growing company. Buy Shares in $LUDG*

If your brokerage firm does not list $LUDG, go for E*TRADE, Scotto Trade or Schwab.

*Investment advice should only be taken at its face value, all investors are advised to conduct their own research with due diligence to make wise decisions.

© PubCo Insight, 2022